Aegerion's JUXTAPID Capsules Approved in Mexico for Treatment of Homozygous Familial Hypercholesterolemia

Aegerion Pharmaceuticals (Nasdaq: AEGR ) today announced that the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) has approved JUXTAPID as an adjunct treatment to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein